



TTAN BIOTECH LIMITED



AN ISO 9001:205 CERTIFICATED COMPANY

Corporate Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India
Tel.: 011-27355742, 71239900 | CIN L74999RJ1992PLC013387

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

13.08.2024

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Tuesday, 13th August, 2024**, at the office of company, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30th June, 2024.
2. Appointment of Cost of Auditor (**Annexure-A**).
M/s Sanjay Kumar Garg & Associates, Cost Accountants, Firm's Registration Number 100292, Cost Accountants has been appointed as the Cost Auditor of the company to conduct the Cost Audit for the financial year 2024-2025. The details as required under Schedule III - Para A(7B) of Part A of the Listing Regulations read with SEBI Circular No CIR/CFD/CMD/4/2015 dated 9th September 2015 is attached below. The said appointment of M/s. Sanjay Kumar Garg & Associates is in compliance with Section 148 of the Companies Act, 2013 and other applicable provisions, if any, read with Companies (Cost Records and Audit) Rules, 2014. The remuneration payable to M/s. Sanjay Kumar Garg & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.
3. Reconstitution of the Stakeholders Relationship Committee (**Annexure-B**).


In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter ended 30th June, 2024.
2. Limited Review Report for the quarter ended 30th June, 2024.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:30 P.M. The above information will be available on the website of the company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking You.
For Titan Biotech Ltd



Charanjit Singh
Company Secretary & Compliance Officer
M.No. A12726
Encl: As above



TITAN BIOTECH LIMITED



AN ISO 9001:205 CERTIFICATED COMPANY

Corporate Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India
Tel.: 011-27355742, 71239900 | CIN L74999RJ1992PLC013387

Annexure-A

SEBI Circular No CIR/CFD/CMD/4/2015 dated 9th September 2015

S.N	PARTICULAR	DISCLOSURE
1	Name of the Cost Auditor	M/s Sanjay Kumar Garg & Associates, Cost Accountants, Firm's Registration Number 100292
2	Reason for change	Appointment as Cost Auditors of the Company.
3	Date of Appointment & term of appointment	August 13, 2024 For conducting Cost Audit of the Company for the F.Y 2024-2025
4	Brief Profile	<p>Mr. Sanjay Kumar Garg (B.COM, FCMA (India), FIPA (Australia), FFA (Australia), CMA (USA), FloV, CIA) is Practicing Cost Accountant having Experience of more than 23 years in the field of Costing, Taxation, Auditing etc. Currently, He is President- of IMA (Institute of Management Accountants) (USA) Delhi Chapter, India.</p> <p>He is also a member of Institute of Public Accountants (Australia), Institute of Financial Accountants (Australia), Certified Management Accountant of Institute of Management Accountant United States of America, Life Member of the Institute of Valuer (New Delhi), Member of Institute of Internal Auditor (Mumbai) and Member of Institute of Directors. He is currently President of Institute of Management Accountants (USA) Delhi Chapter.</p> <p>In Past he was Vice President of Engagement of Institute of Management Accountants (USA) Delhi Chapter, Director of Institute of Management Accountants (USA) Delhi Chapter.</p>
5	Disclosure of relationships between directors	Not Applicable.

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



TITAN BIOTECH LIMITED



AN ISO 9001:205 CERTIFICATED COMPANY


Corporate Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India
Tel.: 011-27355742, 71239900 | **CIN** L74999RJ1992PLC013387

Annexure-B

Details of Reconstitution of Stakeholders Relationship Committee

Stakeholders Relationship Committee	NAME	DESIGNATION
	Rohit Jain	Chairman-Independent Director
	Dhairya Madan	Member- Independent Director
	Naresh Kumar Singla	Member- Executive Director
	Suresh Chand Singla	Member- Executive Director

Thanking You.
Yours faithfully,
For Titan Biotech Ltd



Charanjit Singh
Company Secretary & Compliance Officer
M. No. A12726



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Titan Biotech Limited ('the Company') for the quarter ended 30 June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil Mittal

Digitally signed by Akhil Mittal
DN: c=IN, st=Delhi,
2.5.4.20=80181143796157102660204646110; cn=Akhil Mittal
serialNumber=642773751; postalCode=110026, street=AST
PUNJAB BAGH, Punjab Bagh, West Delhi,
emailAddress=akhil112@gmail.com; o=A N S K & Associates
101110796020646426289; cn=Akhil Mittal
Date: 2024.08.13 14:24:36 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 13.08.2024

Place: New Delhi

UDIN: **24517856BKHCCT1926**



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Titan Biotech Limited ('the Holding Company') and its associate for the quarter ended 30 June 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	4,311.46	3,991.87	3,474.74	16,407.21
	Other Income	62.37	47.72	28.19	174.82
	Total Income	4,373.83	4,039.59	3,502.93	16,582.03
2	EXPENSES				
	Cost of Materials Consumed	2,234.58	2,124.67	1,891.56	8,089.24
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(57.87)	(296.07)	(434.96)	(528.63)
	Employee Benefit Expense	627.06	680.38	541.77	2,371.06
	Finance Costs	30.90	34.08	28.56	117.00
	Depreciation and Amortization Expense	104.73	84.00	79.60	333.06
	Other Expenses	682.73	775.05	687.63	3,047.40
	Total Expenses	3,622.13	3,402.11	2,794.16	13,429.13
3	Profit before exceptional items and tax (1-2)	751.70	637.48	708.77	3,152.90
4	Exceptional Items	-	-	-	-
5	Profit before tax (3+4)	751.70	637.48	708.77	3,152.90
6	Tax expense:				
	(I) Current Tax	181.73	147.34	167.40	778.87
	(II) Earlier year taxes	-	-	(0.31)	(2.90)
	(III) Deferred Tax	0.01	6.02	0.74	10.61
	Total Tax (I+II+III)	181.74	153.36	167.83	786.58
7	Profit for the period (5-6)	569.96	484.12	540.94	2,366.32
8	Share in Profit of Associate	70.00	15.51	75.12	118.98
9	Profit for the period (7+8)	639.96	499.63	616.06	2,485.30
10	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
A.	(ia) Re-measurement gain on defined benefit plans	5.84	17.13	2.08	23.36
	(ii) Income tax relating to these items	(1.47)	(4.31)	(0.53)	(5.88)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	4.37	12.82	1.55	17.48
11	Total Comprehensive Income for the period (7+8)	644.33	512.45	617.61	2,502.78
12	Net profit attributable to:				
	Owners of the holding company				
	Non-controlling interest				
13	Other comprehensive income attributable to :				
	Owners of the holding company				
	Non-controlling interest				
14	Total Comprehensive Income attributable to (10+11)				
	Owners of the holding company				
	Non-controlling interest				
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
16	Other Equity				12,518.75
17	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	7.74	6.05	7.47	30.07
	(2) Diluted	7.74	6.05	7.47	30.07

Notes:

- The above consolidated unaudited financial results for the quarter ended on 30.06.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2024. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter ended June 30, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter ended on 30.06.2024 include the results of following:-
Associate Companies - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June. 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Suresh Chand Singla
SURESH CHAND SINGLA
Managing Director
DIN-00027706



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,373.83	4,039.59	3,502.93	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	751.70	637.48	708.77	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	751.70	637.48	708.77	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	639.96	499.63	616.06	2,485.30
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	644.33	512.45	617.61	2,502.78
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	12,518.75
8	Earnings Per Share (of INR 10/- each)				
	(a) Basic	7.74	6.05	7.47	30.07
	(b) Diluted	7.74	6.05	7.47	30.07

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter ended on 30.06.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter ended on 30th June 2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter ended on 30.06.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Suresh Chand Singla
SURESH CHAND SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated :13.08.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2024

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	4,311.46	3,991.87	3,474.74	16,407.21
	Other Income	62.37	47.72	28.19	174.82
	Total Income	4,373.83	4,039.59	3,502.93	16,582.03
2	EXPENSES				
	Cost of Materials Consumed	2,234.58	2,124.67	1,891.56	8,089.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(57.87)	(296.07)	(434.96)	(528.63)
	Employee Benefits Expense	627.06	680.38	541.77	2,371.06
	Finance Costs	30.90	34.08	28.56	117.00
	Depreciation and Amortization Expense	104.73	84.00	79.60	333.06
	Other Expenses	682.73	775.05	687.63	3,047.40
	Total Expenses	3,622.13	3,402.11	2,794.16	13,429.13
3	Profit before exceptional items and tax (1-2)	751.70	637.48	708.77	3,152.90
4	Exceptional Items	-	-	-	-
5	Profit before tax (3+4)	751.70	637.48	708.77	3,152.90
6	Tax expense:				
	(I) Current Tax	181.73	147.34	167.40	778.87
	(II) Deferred Tax	0.01	6.02	0.74	10.61
	(III) Earlier year taxes	-	-	(0.31)	(2.90)
	Total Tax (I+II+III)	181.74	153.36	167.83	786.58
7	Profit for the period (5-6)	569.96	484.12	540.94	2,366.32
8	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
A.	(ia) Re-measurement gain on defined benefit plans	5.84	17.13	2.08	23.36
	(ii) Income tax relating to these items	(1.47)	(4.31)	(0.53)	(5.88)
B.	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	4.37	12.82	1.55	17.48
9	Total Comprehensive Income for the period (7+8)	574.33	496.94	542.49	2,383.80
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
11	Other Equity				12,017.85
12	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	6.90	5.86	6.55	28.64
	(2) Diluted	6.90	5.86	6.55	28.64

Notes:

- The above standalone unaudited financial results for the quarter ended on 30.06.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter ended June 30, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Suresh Chand Singla
SURESH CHAND SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 13.08.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2024

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,373.83	4,039.59	3,502.93	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	751.70	637.48	708.77	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	751.70	637.48	708.77	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	569.96	484.12	540.94	2,366.32
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	574.33	496.94	542.49	2,383.80
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	12,017.85
8	Earnings Per Share (of INR 10/- each)				
	(a) Basic	6.90	5.86	6.55	28.64
	(b) Diluted	6.90	5.86	6.55	28.64

NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended on 30.06.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended on 30.06.2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above standalone unaudited financial results for the quarter ended on 30.06.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Suresh Chand Singla
SURESH CHAND SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 13.08.2024